We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · May 27, 2022

Efficacy of Lenabasum in Patients With Dermatomyositis and Refractory Skin Disease

Journal of Investigative Dermatology

 

Additional Info

Journal of Investigative Dermatology
Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Dermatomyositis Patients with Refractory Skin Disease A Randomized Clinical Trial
J Invest Dermatol 2022 Apr 28;[EPub Ahead of Print], VP Werth, E Hejazi, SM Pena, J Haber, M Zeidi, N Reddy, J Okawa, R Feng, MM Bashir, K Gebre, AS Jadoo, JSS Concha, N Dgetluck, S Constantine, B White

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading